Holtec Nuclear delays IPO as Nscale eyes multibillion dollar debut
Holtec Nuclear abruptly postponed its $825 million IPO while Nscale filed for a potential $2 billion offering and Electra Therapeutics suffered a rare biotech IPO drop.
SPDR S&P Biotech ETF 1 article
The SPDR S&P Biotech ETF is an exchange-traded fund designed to represent a broad basket of U.S. biotechnology equities through the S&P Biotechnology Select Industry Index. Its equal-weight approach gives smaller and mid-sized companies more influence than market-cap-weighted biotech funds. For biotechnology market analysis, XBI is commonly used as a sector benchmark for risk appetite, relative stock performance and diversified exposure to public drug developers rather than to one therapeutic platform.